From cutting edge science to the impact of Obamacare, from clinical trial results to FDA decisions, and from Bieber fever to hay fever, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments across the health-care industry and their implications for long-term investors. In this week's edition, the team talks about an exciting drug approval, how computers can help scientists develop new drugs, and stocks that have both soared and crashed. The analysts close with a discussion of companies they will be closely following in the coming weeks.
In the segment below, health-care analyst Max Macaluso discusses the upcoming FDA decision for Allergan's (NYSE: AGN) migraine drug Levadex.
The relevant video segment can be found between 13:25 and 15:02.
